AstraZeneca International - pharmaceutical company, prescription drugs, medicine manufacturers

Reference code :: wf5169
Published date :: 18 October 2005
Expired date :: 05 March 2033

AstraZeneca has received a notice from Ranbaxy Pharmaceuticals Inc. that Ranbaxy Laboratories Limited has submitted an Abbreviated New Drug Application (ANDA) for esomeprazole magnesium delayed-release capsules, 20mg and 40mg, containing Paragraph IV Certifications of invalidity and/or non-infringement with respect to certain AstraZeneca US patents listed in the Orange Book in reference to Nexium, the latter of which expires in 2018.

AstraZeneca has 45 days within which to commence a patent infringement lawsuit against Ranbaxy that would automatically stay, or bar, the FDA from approving Ranbaxy's ANDA for 30 months or until an adverse court decision, whichever may occur earlier.

Ranbaxy has also certified with respect to certain other AstraZeneca US patents listed in the Orange Book in reference to Nexium that Ranbaxy will not launch its product prior to the expiry of those patents, the latter of which expires in October 2007.

AstraZeneca is evaluating Ranbaxy's notice and continues to have full confidence in its intellectual property protecting Nexium.

Further enquiries to:

Media Enquiries:
Edel McCaffrey, Tel: +44 (0)20 7304 5034
Steve Brown, Tel: +44 (0)20 7304 5033

Investor Enquiries:
Mina Blair, Tel: +44 (0)20 7304 5084
Jonathan Hunt, Tel: +44 (0)20 7304 5087
Ed Seage, Tel: +1 302 886 4065
Jorgen Winroth, Tel + 1 212 579 0506